Conflicting clinical evidence. The CITRIS-ALI trial showed no improvement in primary outcomes but suggested mortality benefit in secondary analysis. Reduces MDA, and IL-8 in TRALI trial; improves oxygenation and reduces mortality in some COVID-19 studies. Limited by potential oxalate nephropathy risk at high doses. The gene discussed is CXCL8; the disease is COVID-19.